Eligard Dosage
For advanced prostate cancer in adult men, Eligard is available in four FDA-approved depot formulations: 7.5 mg monthly, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months, all administered subcutaneously to achieve and maintain castrate testosterone levels (≤50 ng/dL). 1
Dosing Schedules for Prostate Cancer
The choice among formulations depends primarily on patient preference and convenience, as all achieve equivalent testosterone suppression:
- 7.5 mg: Administered monthly (every 28 days)
- 22.5 mg: Administered every 3 months (every 12 weeks)
- 30 mg: Administered every 4 months (every 16 weeks)
- 45 mg: Administered every 6 months (every 24 weeks)
All formulations achieve castrate testosterone suppression (≤50 ng/dL) in 96-100% of patients by Day 28-42, with sustained suppression throughout the dosing interval 1. Clinical trials demonstrated median testosterone reductions of 94-95% from baseline, with PSA reductions of approximately 95% 2, 3, 4.
Clinical Context for Prostate Cancer
Eligard (leuprorelin/leuprolide acetate) functions as an LHRH agonist for androgen deprivation therapy (ADT). The specific clinical scenarios where ADT is recommended include:
- Metastatic castration-sensitive disease: Continuous ADT is first-line treatment 5
- High-risk localized disease with radiotherapy: Neoadjuvant/concurrent ADT for 4-6 months plus adjuvant ADT for 2-3 years total 6, 5
- Intermediate-risk disease with radiotherapy: Consider 4-6 months of neoadjuvant/concurrent ADT 6
Important caveat: ADT is not recommended as primary treatment for non-metastatic disease without radiotherapy, and should not be used routinely for biochemical recurrence alone unless PSA doubling time is <3 months or metastases are present 5.
Breast Cancer Dosing (Off-Label in Some Regions)
For premenopausal women with hormone receptor-positive breast cancer requiring ovarian suppression:
- 7.5 mg monthly or 22.5 mg every 3 months are both effective options when combined with aromatase inhibitors 7
- Both schedules achieve ovarian ablation (estradiol <40 pg/mL) in 99-100% of patients 7
- The 3-month formulation offers equivalent efficacy with improved convenience 7
Clinical context: Ovarian suppression with leuprolide plus aromatase inhibitor is recommended for premenopausal women with hormone receptor-positive metastatic breast cancer, based on evidence showing improved outcomes compared to tamoxifen alone 8. For adjuvant therapy in early-stage disease, this combination should be considered for higher-risk patients.
Endometriosis Dosing
3.75 mg monthly for 6 months is the established regimen for endometriosis, though this lower dose formulation differs from the Eligard brand depot formulations 9. The 7.5 mg monthly Eligard formulation would provide equivalent ovarian suppression if used off-label for this indication.
Administration Considerations
- All Eligard formulations are administered subcutaneously, typically in the abdomen
- Testosterone levels should be monitored, particularly in the first 1-2 months, to confirm castrate suppression
- Breakthrough testosterone elevation (>50 ng/dL after achieving castration) occurs in <3% of patients 1
- Common adverse effects include hot flashes (most frequent), injection site reactions, sexual dysfunction, and tumor flare in the first 2-4 weeks 2, 4
Monitoring Requirements
For prostate cancer patients:
- Baseline testosterone and PSA levels
- Testosterone at 4 weeks to confirm castrate suppression (<50 ng/dL)
- PSA monitoring every 3-6 months
- Monitor for metabolic syndrome, osteoporosis, and cardiovascular effects during long-term ADT 5
The longer-acting formulations (22.5 mg, 30 mg, 45 mg) offer equivalent efficacy to monthly dosing with significantly improved convenience and adherence, making them preferred options for most patients requiring long-term ADT 10, 2, 3, 4.